The use of intranasal interferon for prevention and treatment of acute respiratory infections

Authors

  • S.О. Kramarov Bogomolets National Medical University, Kyiv, Ukraine
  • V.V. Yevtushenko Bogomolets National Medical University, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2312-413X.9.1.2021.228822

Keywords:

acute respiratory viral infections, interferons, treatment, prevention

Abstract

Interferons are cytokines that are produced by immunocompetent cells in response to the invasion of an infectious factor. The most important biological effect of interferons used in clinical practice is their ability to nonspecifically inhibit viral replication. This article summarizes the functions of interferons in the implementation of the functions of innate and acquired immunity. The possibilities of using intranasal interferons for the treatment and prevention of the most common viral diseases in children, in particular acute respiratory viral infections, SARS and SARS-CoV-2, are considered.

References

Fensterl V., Sen G.C. Interferons and viral infections. BioFactors [Internet]. John Wiley & Sons, Ltd. 2009. 35. 14-20. Available from: https://doi.org/10.1002/biof.6.

Zhou A., Li S., Wu J., Khan F.A., Zhang S. Interplay between microRNAs and host pathogen recognition receptors (PRRs) signaling pathways in response to viral infection. Virus Res. Netherlands. 2014. 184. 1-6.

Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. England. 2011. 30. 16-34.

Durbin R.K., Kotenko S.V., Durbin J.E. Interferon induction and function at the mucosal surface. Immunol. Rev. [Internet]. 2013. 255. 25-39. Available from: https://pubmed.ncbi.nlm.nih.gov/23947345.

Rowe R.K., Pyle D.M., Farrar J.D., Gill M.A. Type I interferon regulates IgE-mediated enhancement of rhinovirus-induced Th2 priming by primary human monocytes. bioRxiv [Internet]. 2018. 432815. Available from: http://biorxiv.org/content/early/2018/10/08/432815.abstract.

José R.J. Respiratory infections: a global burden. Ann. Res. Hosp. [Internet]. 2018 [cited 2019 Sep 15]. 2. 12-12. Available from: http://arh.amegroups.com/article/view/4514/5468.

Tregoning J.S., Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. [Internet]. American Society for Microbiology (ASM). 2010 [cited 2019 Sep 15]. 23. 74-98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20065326.

Kugel D., Kochs G., Obojes K., Roth J., Kobinger G.P., Kobasa D. et al. Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets. J. Virol. [Internet]. 2009. 83. 3843 LP-3851. Available from: http://jvi.asm.org/content/83/8/3843.abstract.

Лиманская А., Давыдова Ю. Препараты интерферона в лечении острых респираторных вирусных инфекций у беременных группы высокого риска. Здоровье женщины. 2015. 9. 74-6.

Воробьев А.А., Афанасьев С.С., Рубальский О.В., Алешкин В.А., Башкина О.А., Кокуев А.В. и др. Эффект лечения рецидивирующего бронхита у детей комбинированными интерфероновыми препаратами при различных путях аппликации. Журнал микробиологии, эпидемиологии и иммунобиологии. 2005. 3. 99-102.

Kneyber M.C., Moll H.A., de Groot R. Treatment and prevention of respiratory syncytial virus infection. Eur. J. Pediatr. Germany. 2000. 159. 399-411.

Образцова Е.В., Осидак Л.В., Афанасьева О.И., Головачева Е.Г., Милькинт К.К., Протасова С.Ф. и др. Препараты рекомбинантного интерферона альфа-2 в лечении острых респираторных инфекций у детей. Детские инфекции [Internet]. 2005. 2. 46-50. Available from: https://cyberleninka.ru/article/n/preparaty-rekombinantnogo-interferona-alfa-2-v-lechenii-ostryh-respiratornyh-infektsiy-u-detey.

Буряк В.Н., Такташов С.И., Махмутов Р.Ф., Пошехонова Ю.В., Шабан Н.И., Моисеева Т.Ю. Клинико-патогенетические аспекты и оптимизация терапевтических подходов при острых респираторно-вирусных инфекциях у детей. Современная педиатрия. 2014. 4. 72-6.

Baron S., Tyring S.K., Fleischmann W.R.J., Coppenhaver D.H., Niesel D.W., Klimpel G.R. et al. The interferons. Mechanisms of action and clinical applications. JAMA. United States. 1991. 266. 1375-83.

Boxx G.M., Cheng G. The Roles of Type I Interferon in Bacterial Infection. Cell. Host. Microbe [Internet]. 2016. 19. 760-9. Available from: https://pubmed.ncbi.nlm.nih.gov/27281568.

Феклисова Л., Шебекова В., Целипанова Е., Михайлова Н., Гапонюк П. Гриппферон у детей, больных ОРВИ. Врач. 2001. 3. 40-1.

Cantell K. Development of antiviral therapy with alpha interferons: promises, false hopes and accomplishments. Ann. Med. England. 1995. 27. 23-8.

Москалюк В.Д. Лаферон у комплексному лікуванні хворих на грип А. Інфекційні хвороби. 2004. 1. 32-4.

Чернышева О.Е., Сорока Ю.А., Фоменко Т.А., Левченко С.А., Баева В.Г., Вьюниченко Ю.С. Интерферонотерапия в лечении острых респираторных вирусных заболеваний у детей. Здоровье ребенка. 2011. 6. 41-5.

Крамарєв С.О., Мальцев В.І., Казимирко В.К. Грипферон як ефективний засіб профілактики та лікування грипу й інших ГРВІ. Інфекційні хвороби. 2003. 1. 22-4.

Крамарьов С.О., Євтушенко В.В. Оцінка ефективності рекомбінантного інтерферону альфа для профілактики та лікування гострих респіраторних вірусних інфекцій та грипу в дітей. Сімейна медицина. 2008. 4. 19-22.

Кривопустов С.П. Интраназальное применение рекомбинантного интерферона альфа в педиатрии. Здоров’я України. 2010. 32.

Herzog C., Berger R., Fernex M., Friesecke K., Havas L., Just M. et al. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study. Antiviral. Res. Netherlands. 1986. 6. 171-6.

Hayden F.G., Albrecht J.K., Kaiser D.L., Gwaltney J.M. Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha2-Interferon. N. Engl. J. Med. [Internet]. Massachusetts Medical Society. 1986. 314. 71-5. Available from: https://doi.org/10.1056/NEJM198601093140202.

Yu D., Chen Q., Zhang L., Liu Y., Yu Z., Li Z. et al. A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi [Internet]. 2005 [cited 2016 Apr 26]. 19. 216-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16261200.

Zhao J., Zhu F., Shu Y., Zhou R., Liu L., Zhang L. et al. Preliminary study on nasal spray of interferon alpha-2b used for prevention of rubella and measles virus infections. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi [Internet]. 2005 [cited 2016 Apr 26]. 19. 220-2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16261201.

Acharya D., Liu G., Gack M.U. Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. [Internet]. 2020. 20. 397-8. Available from: https://doi.org/10.1038/s41577-020-0346-x.

Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science [Internet]. 2020. 369. 718 LP-724. Available from: http://science.sciencemag.org/content/369/6504/718.abstract.

Park A., Iwasaki A. Type I and Type III Interferons — Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell. Host. Microbe [Internet]. Elsevier Inc. 2020. 27. 870-8. Available from: https://doi.org/10.1016/j.chom.2020.05.008.

Lokugamage K.G., Hage A., Schindewolf C., Rajsbaum R., Menachery V.D. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv [Internet]. 2020. 2020.03.07. 982264. Available from: http://biorxiv.org/content/early/2020/03/18/2020.03.07.982264.abstract.

Sallard E., Lescure F.-X., Yazdanpanah Y., Mentre F., Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral. Res. [Internet]. 2020. 178. 104791. Available from: http://www.sciencedirect.com/science/article/pii/S0166354220302059.

Wang N., Zhan Y., Zhu L., Hou Z., Liu F., Song P. et al. Retrospective Multicenter Cohort Study Shows Early Interferon The­rapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell. Host. Microbe [Internet]. 2020/07/18. Elsevier Inc. 2020. 28. 455-464.e2. Available from: https://pubmed.ncbi.nlm.nih.gov/32707096.

Zhou Q., Wei X.-S., Xiang X., Wang X., Wang Z.-H., Chen V. et al. Interferon-a2b treatment for COVID-19. medRxiv [Internet]. 2020. 2020.04.06. 20042580. Available from: http://medrxiv.org/content/early/2020/04/10/2020.04.06.20042580.abstract.

Meng Z., Wang T., Li C., Chen X., Li L., Qin X. et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv [Internet]. 2020. 2020.04.11. 20061473. Available from: http://medrxiv.org/content/early/2020/05/07/2020.04.11.20061473.abstract.

Published

2021-04-22

Issue

Section

Lecture